Scientists at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have identified NLRP3 inflammasome inhibitors reported to be useful for the treatment of cardiovascular disorders.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have described hypoxia inducible factor-2α (HIF-2α; EPAS1) inhibitors reported to be useful for treatment of ulcerative colitis and Crohn’s disease.
Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have synthesized 3C-like proteinase (3CLpro, Mpro) (coronavirus) inhibitors reported to be useful for the treatment of coronavirus acute respiratory syndrome infections.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have identified new monoglyceride lipase (MGLL; MAGL) inhibitors reported to be useful for the treatment of pain, cancer, inflammatory bowel disease, endometriosis, asthma, mental diseases and neurological and renal disorders.
Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have described bicyclic tetrahydrothiazepine derivatives acting as diacylglycerol kinase α (DGK-α, DGKA) and/or diacylglycerol kinase ζ (DGK-ζ, DGKZ) inhibitors reported to be useful for the treatment of cancer.
Novel pyrimidinyl and triazinyl sulfonamide derivatives acting as uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-like) antagonists have been reported in an F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. patent.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have patented phosphorylpurinone compounds acting as Toll-like receptor 7 (TLR7) agonists reported to be useful for the treatment of cancer.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have described new 5’-nucleotidase (CD73) inhibitors reported to be useful for the treatment of cancer.
Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have described imidazo[4,5-b]pyridine and pyrazolo[1,5-a]pyrimidine derivatives acting as serine/threonine-protein kinase SIK inhibitors reported to be useful for the treatment of juvenile idiopathic arthritis, nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis, inflammatory bowel disease, atherosclerosis, type 2 diabetes and glomerulonephritis, among others.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche, Inc. have described fluorescent probes acting as monoglyceride lipase (MGLL; MAGL) inhibitors reported to be useful for diagnostic imaging of MAGL.
